Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500266 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,053
- Enrollment target
NCT00500266 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,053 participants.
The verdict
NCT00500266, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,053 participants
- Enrollment target
Study Summary
To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.
Interventions
- BIOLOGICAL 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,053 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500266
The ClinicalTrials.gov registry entry for NCT00500266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,053 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 13-valent Pneumococcal Conjugate Vaccine (13vPnC) is the first listed.
NCT00500266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500266 about?
NCT00500266 is a clinical study titled "Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects". To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.
What is the current status of trial NCT00500266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,053 participants. The study started on 2008-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00500266?
The interventions under investigation include: 13-valent Pneumococcal Conjugate Vaccine (13vPnC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00500266?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.